197 related articles for article (PubMed ID: 24906862)
1. Geospatial distribution and clustering of Chlamydia trachomatis in communities undergoing mass azithromycin treatment.
Yohannan J; He B; Wang J; Greene G; Schein Y; Mkocha H; Munoz B; Quinn TC; Gaydos C; West SK
Invest Ophthalmol Vis Sci; 2014 Jun; 55(7):4144-50. PubMed ID: 24906862
[TBL] [Abstract][Full Text] [Related]
2. Spatial clustering of ocular chlamydial infection over time following treatment, among households in a village in Tanzania.
Broman AT; Shum K; Munoz B; Duncan DD; West SK
Invest Ophthalmol Vis Sci; 2006 Jan; 47(1):99-104. PubMed ID: 16384950
[TBL] [Abstract][Full Text] [Related]
3. The effect of multiple rounds of mass drug administration on the association between ocular Chlamydia trachomatis infection and follicular trachoma in preschool-aged children.
Lee JS; Muñoz BE; Mkocha H; Gaydos CA; Quinn TC; West SK
PLoS Negl Trop Dis; 2014 Apr; 8(4):e2761. PubMed ID: 24722392
[TBL] [Abstract][Full Text] [Related]
4. A Longitudinal Analysis of Chlamydial Infection and Trachomatous Inflammation Following Mass Azithromycin Distribution.
Morberg DP; Alemayehu W; Melese M; Lakew T; Sisay A; Zhou Z; Cevallos V; Oldenburg CE; Porco TC; Lietman TM; Keenan JD
Ophthalmic Epidemiol; 2019 Feb; 26(1):19-26. PubMed ID: 30153085
[TBL] [Abstract][Full Text] [Related]
5. Trachoma and ocular Chlamydia trachomatis were not eliminated three years after two rounds of mass treatment in a trachoma hyperendemic village.
West SK; Munoz B; Mkocha H; Gaydos C; Quinn T
Invest Ophthalmol Vis Sci; 2007 Apr; 48(4):1492-7. PubMed ID: 17389476
[TBL] [Abstract][Full Text] [Related]
6. Risk of Infection with Chlamydia trachomatis from Migrants to Communities Undergoing Mass Drug Administration for Trachoma Control.
West SK; Munoz BE; Mkocha H; Gaydos C; Quinn T
Ophthalmic Epidemiol; 2015; 22(3):170-5. PubMed ID: 26158574
[TBL] [Abstract][Full Text] [Related]
7. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results.
Yohannan J; Munoz B; Mkocha H; Gaydos CA; Bailey R; Lietman TA; Quinn T; West SK
JAMA Ophthalmol; 2013 Apr; 131(4):431-6. PubMed ID: 23392481
[TBL] [Abstract][Full Text] [Related]
8. Impact of a single round of mass drug administration with azithromycin on active trachoma and ocular Chlamydia trachomatis prevalence and circulating strains in The Gambia and Senegal.
Harding-Esch EM; Holland MJ; Schémann JF; Sillah A; Sarr B; Christerson L; Pickering H; Molina-Gonzalez S; Sarr I; Andreasen AA; Jeffries D; Grundy C; Mabey DCW; Herrmann B; Bailey RL
Parasit Vectors; 2019 Oct; 12(1):497. PubMed ID: 31640755
[TBL] [Abstract][Full Text] [Related]
9. Community-level Association between Clinical Trachoma and Ocular Chlamydia Infection after MASS Azithromycin Distribution in a Mesoendemic Region of Niger.
Amza A; Kadri B; Nassirou B; Cotter SY; Stoller NE; West SK; Bailey RL; Porco TC; Keenan JD; Lietman TM; Oldenburg CE
Ophthalmic Epidemiol; 2019 Aug; 26(4):231-237. PubMed ID: 30957594
[No Abstract] [Full Text] [Related]
10. Is there evidence for resistance of ocular Chlamydia trachomatis to azithromycin after mass treatment for trachoma control?
West SK; Moncada J; Munoz B; Mkocha H; Storey P; Hardick J; Gaydos CA; Quinn TC; Schachter J
J Infect Dis; 2014 Jul; 210(1):65-71. PubMed ID: 24446528
[TBL] [Abstract][Full Text] [Related]
11. Mass azithromycin distribution for hyperendemic trachoma following a cluster-randomized trial: A continuation study of randomly reassigned subclusters (TANA II).
Keenan JD; Tadesse Z; Gebresillasie S; Shiferaw A; Zerihun M; Emerson PM; Callahan K; Cotter SY; Stoller NE; Porco TC; Oldenburg CE; Lietman TM
PLoS Med; 2018 Aug; 15(8):e1002633. PubMed ID: 30106956
[TBL] [Abstract][Full Text] [Related]
12. The impact of a single round of community mass treatment with azithromycin on disease severity and ocular Chlamydia trachomatis load in treatment-naïve trachoma-endemic island communities in West Africa.
Last AR; Burr SE; Harding-Esch E; Cassama E; Nabicassa M; Roberts CH; Mabey DCW; Holland MJ; Bailey RL
Parasit Vectors; 2017 Dec; 10(1):624. PubMed ID: 29282126
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for ocular infection with Chlamydia trachomatis in children 6 months following mass treatment in Tanzania.
Cajas-Monson LC; Mkocha H; Muñoz B; Quinn TC; Gaydos CA; West SK
PLoS Negl Trop Dis; 2011 Mar; 5(3):e978. PubMed ID: 21423645
[TBL] [Abstract][Full Text] [Related]
14. Targeting antibiotics to households for trachoma control.
Blake IM; Burton MJ; Solomon AW; West SK; Basáñez MG; Gambhir M; Bailey RL; Mabey DC; Grassly NC
PLoS Negl Trop Dis; 2010 Nov; 4(11):e862. PubMed ID: 21072225
[TBL] [Abstract][Full Text] [Related]
15. The conjunctival microbiome before and after azithromycin mass drug administration for trachoma control in a cohort of Tanzanian children.
Pickering H; Ramadhani AM; Massae P; Mafuru E; Malisa A; Mbuya K; Makupa W; Mtuy T; Derrick T; Houghton J; Bailey RL; Mabey DCW; Burton MJ; Holland MJ
Front Public Health; 2022; 10():1015714. PubMed ID: 36324475
[TBL] [Abstract][Full Text] [Related]
16. Chlamydial positivity of nasal discharge at baseline is associated with ocular chlamydial positivity 2 months following azithromycin treatment.
Gower EW; Solomon AW; Burton MJ; Aguirre A; Muñoz B; Bailey R; Holland M; Makalo P; Massae P; Mkocha H; Mabey DC; West SK
Invest Ophthalmol Vis Sci; 2006 Nov; 47(11):4767-71. PubMed ID: 17065486
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for ocular chlamydia after three mass azithromycin distributions.
Ayele B; Gebre T; Moncada J; House JI; Stoller NE; Zhou Z; Porco TC; Gaynor BD; Emerson PM; Schachter J; Keenan JD
PLoS Negl Trop Dis; 2011 Dec; 5(12):e1441. PubMed ID: 22180804
[TBL] [Abstract][Full Text] [Related]
18. Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation (ASANTE) Trial: Design and Baseline Characteristics.
Ervin AM; Mkocha H; Munoz B; Dreger K; Dize L; Gaydos C; Quinn TC; West SK
Ophthalmic Epidemiol; 2016 Dec; 23(6):347-353. PubMed ID: 27820670
[TBL] [Abstract][Full Text] [Related]
19. Ocular immune responses, Chlamydia trachomatis infection and clinical signs of trachoma before and after azithromycin mass drug administration in a treatment naïve trachoma-endemic Tanzanian community.
Ramadhani AM; Derrick T; Macleod D; Massae P; Malisa A; Mbuya K; Mtuy T; Makupa W; Roberts CH; Bailey RL; Mabey DCW; Holland MJ; Burton MJ
PLoS Negl Trop Dis; 2019 Jul; 13(7):e0007559. PubMed ID: 31306419
[TBL] [Abstract][Full Text] [Related]
20. Stopping azithromycin mass drug administration for trachoma: A systematic review.
Mahmud H; Landskroner E; Amza A; Aragie S; Godwin WW; de Hostos Barth A; O'Brien KS; Lietman TM; Oldenburg CE
PLoS Negl Trop Dis; 2021 Jul; 15(7):e0009491. PubMed ID: 34237074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
